Off-Label Promotion Settlement Includes Optional Preclearance Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Amarin may submit up to two proposed communications annually about unapproved use of Vascepa, and FDA must respond with any concerns within 60 calendar days.
You may also be interested in...
Omega-3 Drug Firm’s Trade Complaint Questions US Dietary Ingredient Standards
Amarin targets purified EPA dietary supplements or formulations containing primarily EPA in ethyl ester or re-esterified form and raises general questions about using synthetic dietary ingredients in supplements and about the extent to which a substance’s previous identification as an IND candidate precludes its subsequent use as a dietary ingredient.
Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements
Seeking to protect its competitive interests, Vascepa marketer asks the US International Trade Commission to investigate importation and sale of synthetically produced omega-3 products by 18 companies; complaint asserts the products at issue are unapproved new drugs that are illegally being marketed as dietary supplements.
Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements
Seeking to protect its competitive interests, Vascepa marketer asks the US International Trade Commission to investigate importation and sale of synthetically produced omega-3 products by 18 companies; complaint asserts the products at issue are unapproved new drugs that are illegally being marketed as dietary supplements.